Exhibit Hall

HomeAttendeesExhibit Hall ▶ Industry Theaters
Industry Theaters

Have lunch while listening to the latest clinical updates from supporting companies related to pulmonary, critical care, or sleep medicine.

Industry Theaters and Mini Industry Theaters are available on Sunday, Monday, and Tuesday in the Exhibit Hall.

Complimentary boxed lunch provided by the ATS (while quantities last).


Sunday, May 21

Industry Theater 1

11:30 a.m. to 12:15 p.m.

Advancing the Treatment of IPF: A Patient Journey (Open to U.S. attendees only)

Please join our expert Pulmonologist for an engaging case-based presentation about the treatment and management of IPF. Attendees will gain an increased understanding of IPF, treatment with an FDA-approved IPF specific therapy, and suggestions for managing patients during their journey with IPF.

The program will review:
• Treatment upon diagnosis
• Setting treatment goals and expectations with IPF patients
• Managing IPF patients on an FDA-approved IPF specific therapy

Speaker: Daniel Dilling, MD, Loyola University Hospital Maywood, IL
Company: Genentech, A Member of the Roche Group

1:15 to 2 p.m.

COPD Treatment Strategy for 2017 (Open to International attendees only)

The GOLD report provides clinicians with an evidence-based reference tool to effectively manage the diagnosis and treatment of COPD. In the 2017 edition, the pivotal treatment goals of alleviating symptoms and reducing exacerbation risk remains unchanged. However, the updated guidelines, now gives physicians more clarity on those patients initially suited for treatment with bronchodilators and those which may require additional therapy. This industry theatre will focus on the importance of LAMA+LABA in maximising bronchodilation and the benefits of escalation to triple therapy, with the addition of an ICS,
for patients with persistent exacerbations. These GOLD recommendations provide physicians with the options to use a more personalised treatment approach.

Speakers: Christopher Cooper, BSc, MB, BS, MD(Lond), MD(ECFMG), MS, FRCP, FACSM, FCCP, Professor, Global Respiratory Franchise, GSK, US; Dave Singh, BA (Hons), MB, B.Chir, MA (Hon), MRCP, MD, Professor, University of Manchester, Manchester, UK; Neil Barnes, BA Hons, MA, LRCP, MRCS, MBBS FRCP, Professor, Global Respiratory Franchise, GSK, UK.
Company: GSK GlaxoSmithKline

Industry Theater 2

11:30 a.m. to 12:15 p.m.

Progressing the COPD Treatment Strategy: A Central Role for Dual Bronchodilation (Open to International attendees only)

During this Novartis supported Industry Theater, a faculty of world-renowned experts will summarize recent developments in COPD management, focusing on the updated position of dual bronchodilation in treatment recommendations. The practicalities of implementing new recommendations in clinical practice will be explored, with emphasis on assessing benefit/risk when determining appropriate treatment.

Speakers: Ken Chapman, MD, Professor of Medicine, University of Toronto, Canada; Marc Miravitlles, MD, Pulmonologist, Vall d’Hebron University Hospital, Barcelona; Dave Singh, MD, Professor of Clinical Pharmacology and Respiratory Medicine, University Hospital of South Manchester
Company: Novartis Pharma AG

1:15 to 2 p.m.

Is ICS Really the Answer to Reducing the Risk of Exacerbations?

Dr Ferguson and Dr Anzueto will present clinical data on how COPD maintenance therapies reduce the risk of exacerbations and debate the effectiveness of LAMA/LABAs versus ICS-containing therapies. They will also discuss how recent data has led to updated GOLD treatment recommendations favoring LAMA/LABA as a preferred treatment option for most patients with COPD, and the implications for clinical practice.

Speakers: Gary T Ferguson, MD, Director, Pulmonary Research Institute of Southeast Michigan; Antonio Anzueto, MD, Professor - Department of Pulmonary Diseases and Critical Care Medicine, University of Texas Health Science Center at San Antonio
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Mini Industry Theater

11:30 a.m. to Noon

Clinical and Practical Consideration for Prostacyclin Analogue Use Across a PAH Continuum of Care (Open to U.S. attendees only)

Through the course of your patient’s journey with PAH, they may be treated with a prostacyclin analogue, which may be available in multiple routes of administration—oral, inhaled, subcutaneous, and intravenous. This session will cover why these therapies may be important for treating your patients with this progressive disease. 

Speaker: Ronald J. Oudiz, MD, FACP, FACC, FCCP, Professor of Medicine (The David Geffen School of Medicine at UCLA), Director, Liu Center for Pulmonary Hypertension (LA Biomedical Research Institute at Harbor-UCLA Medical Center) Torrance, CA
Company: United Therapeutics

1:30 to 2 p.m.

Know Your Patient Goals: Understanding the Goal-Oriented Approach in PAH (WHO Group 1)

When discussing PAH treatment options, what goals do you set for you adult PAH (WHO Group 1) patients? A PAH Expert will present and discuss cases targeting the NO-sGC-cGMP pathway and review a goal-oriented approach in PAH.

Speaker: Chad E. Miller, MD, Program Director, Pulmonary Vascular Disease Piedmont Healthcare
Company: Bayer

[Back to Top]

Monday, May 22

Industry Theater 1

11:30 a.m. to 12:15 p.m.

Expert Perspectives: Allergic Asthma

Join esteemed allergic asthma experts as they share their perspectives on the management of moderate-to-severe allergic asthma at this lunch industry theater. These experts will engage participants in a series of presentations on topics such as the burden of uncontrolled allergic asthma and the efficacy and safety profile of an FDA‐approved therapy.

Companies: Genentech USA, Inc. and Novartis Pharmaceuticals Corporation

1:15 to 2 p.m.

Assessing the Patient: The Role of Maximizing Bronchodilation in COPD

There can be varied presentations of impaired lung function in COPD patients, with symptoms having a significant impact. The focus of this program is to provide healthcare professionals with information to understand air-trapping, hyperinflation, and inspiratory capacity in COPD. The program will include a review of a product for the maintenance treatment of COPD.

Speakers: Donald Tashkin, MD, Professor Emeritus of Medicine, David Geffen School of Medicine, UCLA; Ronald Balkissoon, MD, MSc, Pulmonary Consultant
Company: AstraZeneca

Industry Theater 2

11:30 a.m. to 12:15 p.m.

Salford Lung Study; Closing the Gap Between Effectiveness and Efficacy (Open to International attendees only)

The Salford Lung Study in COPD (SLS COPD) is an open label randomized controlled trial that aims to guide COPD treatment choices by generating effectiveness and safety data in UK primary care, in a population intended to represent that seen in everyday clinical practice. It is the first study of its kind to explore the effectiveness and safety of initiating Fluticasone furoate/vilanterol (which was pre-licensed at study start) compared with continuing usual COPD treatments. A second study in asthma (SLS Asthma) has also been conducted. This industry theatre will seek to investigate some of the many challenges faced in the design, execution and analysis of these studies. SLS is pioneering in its many collaborations between GSK, academia, pharmacies, primary and secondary healthcare.

Speakers: Mark Forshag, MD, MHA, Dr, GlaxoSmithKline, US; Ashley Woodcock, OBE, MD, BSc, MB ChB, FRCP, FERS, FMedSci, Professor, University of Manchester, Manchester, UK; David Leather, MB ChB, FRCGP, DCH, DRCOG, Dip Adv Ther, MFPM, Dr, Global Respiratory Franchise, GSK, UK.
Company: GSK GlaxoSmithKline

1:15 to 2 p.m.

Treatment Strategy with NUCALA® (mepolizumab) (Complimentary boxed lunch provided by GSK, while quantities last)

GSK invites you to an overview of the clinical development program for NUCALA, which will include the efficacy and safety profile. At the end of this program you will be able to identify the appropriate patients for NUCALA.

Speaker: Mark Forshag, MD, MHA, US Medical Expert, GSK
Company: GlaxoSmithKline

Mini Industry Theater

11:30 a.m. to Noon

Lung Cancer and the Pulmonologist in 2017

This presentation will highlight the changing landscape of lung cancer treatment, evolving role of the pulmonologist in the multidisciplinary team and ongoing innovations in research and development.

Speakers: Dr. Benjamin Kramer, MD, Vice President of Immunology & Ophthalmology, Genentech US Medical Affairs; Dr. Praveen R. Chenna, MD, Assistant Professor of Medicine, Assistant Director of Interventional Pulmonology, Program Director - Interventional Pulmonology Fellowship, Washington University in St. Louis
Company: Genentech, A Member of the Roche Group

12:30 to 1 p.m.

LABA/LAMA: An Update in the Management of COPD

Speaker: Antonio Anzueto, MD, Professor of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, Consultant of Sunovion Pharmaceuticals Inc.
Company: Sunovion Pharmaceuticals Inc.

1:30 to 2 p.m.

Optimizing the Patient Experience with Oral Prostacylin-Class Therapy (Open to U.S. attendees only)
The advent of oral prostacyclin-class therapy simplifies patient access to treatment for this established PAH therapeutic pathway. With a shift in prescribing patterns to earlier initiation of prostacyclin treatment, this session will focus on prostacyclin effects, the importance of setting expectations for therapy, and the impact of ongoing HCP-patient communications, including education, through the course of treatment.

Company: United Therapeutics

[Back to Top]

Tuesday, May 23

Industry Theater 1

11:30 a.m. to 12:15 p.m.

Perspective on the Early and Accurate Diagnosis of IPF

This disease state program will focus on understanding how to diagnose IPF earlier, with an emphasis on the benefit for patients of starting appropriate interventions promptly.

Speaker: Marilyn K. Glassberg, MD, Professor of Medicine, Surgery and Pediatrics; Director, Rare and Interstitial Lung Disease Program, University of Miami Miller School of Medicine.
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

1:15 to 2 p.m.

A Different Approach to Treating Uncontrolled Asthma: A Case Based Discussion (Open to U.S. attendees only)

The role of an anticholinergic in treating patients with uncontrolled asthma.

Speakers: Joann Blessing-Moore, MD Allergist/Immunologist, Stanford University Hospital; Mark Millard, MD, Pulmonologist, Baylor Martha Foster Lung Center
Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Industry Theater 2

11:30 a.m. to 12:15 p.m.

Revolutionary Pulmonary Embolism Intervention

Learn about a rapid catheter-directed thrombolysis protocol for treating PE!  If you want to move beyond the status quo for managing PE and proactively elevate your quality of care, join us and learn how a low-dose, short treatment-time procedure can transform your interventional options for PE.

Speaker: Victor F. Tapson, MD, FCCP, FRCP, Professor of Medicine, Cedars-Sinai Medical Center.
Company: EKOS Corporation, a BTG International group company

1:15 to 2 p.m.

Real-World Treatment of COPD: A Case-Based Look at Perforomist® (Formoterol Fumarate) Inhalation Solution (Open to U.S. attendees only)

Join Dr. Robert Sussman as he reviews real-world patient case studies and provides clinical evidence in support of PERFOROMIST Inhalation Solution for the maintenance of COPD. This program is sponsored by Mylan Specialty L.P. Lunch will be provided. Due to regulatory restrictions, this program is only available to attendees from the United States.

Speaker: Robert Sussman, MD, Medical Director, Atlantic Respiratory Institute, Overlook Medical Center Summit, NJ
Company: Mylan Specialty L.P.

Mini Industry Theater

11:30 a.m. to Noon

Right Patient, Right Device: The Importance of Device Choice in Personalizing COPD Treatment

COPD patients are diverse in their presentation and treatment needs. Personalizing the management of COPD requires the selection of both the right therapeutic agents and the right delivery device. While there is guidance for the choice of pharmacologic treatment in COPD, selecting the most appropriate delivery device for each patient can be challenging. Join an expert pulmonologist for a presentation on the variety of device options available for COPD and considerations in selecting the right one for your patient.

Speaker: James F. Donohue, MD, Professor of Medicine, Chief of the Division of Pulmonary & Critical Care Medicine, University of North Carolina at Chapel Hill School of Medicine.

Company: AstraZeneca

12:30 to 1 p.m.

Saving Lives with Nasal High Flow Therapy
During this Industry Theater Dr JP Frat shall share his clinical expertise regarding nasal high flow therapy. Delegates will be provided with invaluable practical insights. This educational activity is not accredited. The program content was developed in conjunction with Fisher & Paykel Healthcare Ltd.

Speaker:Jean-Pierre Frat, MD, Dr, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
Company: Fisher & Paykel Healthcare Ltd.

1:30 to 2 p.m.

Evidence for Home NIV in COPD: Clinical Implications of the HOT-HMV Trial

HOT-HMV: study objectives, methodology and results along with the clinical implications for using noninvasive ventilation in the home for COPD.

Speaker: Nicholas Hart, BSc PhD MRCP FFICM, Clinical and Academic Director, Lane Fox Respiratory Unit, Guy’s & St Thomas’ NHS Foundation Trust and St Thomas’ Hospital; and Reader in Respiratory & Critical Care Medicine, Department of Asthma, Allergy and Respiratory Science, Division of Asthma, Allergy and Lung Biology, King’s College, London, United Kingdom
Company: Philips Respironics

[Back to Top]